Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8076 | 0.84 | DRD2 (0.37) | DRD2DRD3 | |
| SCHEMBL12061561 | 0.82 | SLC6A4 (0.43) | — | |
| SCHEMBL14551 | 0.79 | ADRA1D (0.52) | DRD2SIGMAR1DRD3 | |
| SCHEMBL14077 | 0.77 | SLC6A4 (0.47) | DRD2DRD3 | |
| SCHEMBL6133832 | 0.71 | CCR2 (0.66) | — | |
| SCHEMBL5705202 | 0.68 | DRD2 (0.54) | DRD2SIGMAR1 | |
| SCHEMBL13799 | 0.68 | CA5A (0.41) | — | |
| SCHEMBL6848950 | 0.67 | DRD2 (0.55) | DRD2SIGMAR1FAAHDRD3 | |
| SCHEMBL7386808 | 0.67 | BCHE (0.57) | DRD2 | |
| SCHEMBL7388282 | 0.67 | BCHE (0.57) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | DRD2 2468/4885CAMK2D 4636/4885ADRA2C 4387/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | DRD2 2468/4885CAMK2D 4636/4885ADRA2C 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.